New hope for Tough-to-Treat breast cancer: Two-Drug combo tested
NCT ID NCT02860000
Summary
This study tested whether adding the hormone therapy fulvestrant to a new drug called alisertib works better than alisertib alone for women with advanced breast cancer that has spread and stopped responding to standard hormone treatments. It involved 96 postmenopausal women. Researchers compared tumor shrinkage and time until the cancer worsened between the two treatment groups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
Vanderbilt Breast Center at One Hundred Oaks
Nashville, Tennessee, 37204, United States
Conditions
Explore the condition pages connected to this study.